|
FDA Questions GPhA’s Stability Requests Because of Recall Data
FDA statistics show more than one-third of all drug recalls last year were due to stability failures — a figure that suggests the generic industry’s call for stability testing flexibility in a forthcoming guidance is unwarranted, agency officials say.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives